Tying payment incentives to quality measurement

Abstract

The most important lesson from this program has been that collaboration, data, and measured performance are all possible for cancer care.

Figure 1.

Time-to-progression calculations for patients with relapse measures, calculated from the date of episode enrollment. Numbers appearing above the bars indicate the number of patients.

Figure 2.

Rates of emergency room visits and hospital days for cancer and treatment morbidities in patients with lung cancer. Raw inpatient days and emergency room visits are indicated in brackets: [inpatient days, emergency room visits].

Figure 3.

Average total cost per episode for patients with early-stage breast cancer whose tumors are positive for hormone receptors and underexpress the HER2 gene. Values after bars indicate number of episodes. ASP, average sales price. (*)Includes emergency room visits without admission, outpatient hospital, all physician, and ancillary costs.

Figure 4.

Diagnostic radiology cost and use in patients with metastatic cancer for a 4-month episode. Numbers to the right of bars indicate the number of procedures:number of episodes.